Featured Research

from universities, journals, and other organizations

Needle-free, Inhalant Powder Measles Vaccine Could Save Thousands Of Lives

Date:
August 18, 2009
Source:
American Chemical Society
Summary:
The first inhalable vaccine for measles is moving toward clinical trials next year in India, where the disease still sickens millions of infants and children and kills almost 200,000 annually, according to researchers. The dry-powder vaccine is a perfect fit for use in back-roads areas of developing countries that may lack access to electricity and needles, the scientists say.

Scientists have developed the first dry powder inhalable vaccine for measles. The inhaler is easy to use.
Credit: Aktiv-Dry, LLC

The first dry powder inhalable vaccine for measles is moving toward clinical trials next year in India, where the disease still sickens millions of infants and children and kills almost 200,000 annually, according to a report presented at the 238th National Meeting of the American Chemical Society (ACS).

Robert Sievers, Ph.D., who leads the team that developed the dry-powder vaccine, said it's a perfect fit for use in back-roads areas of developing countries. Those areas often lack the electricity for refrigeration, clean water and sterile needles needed to administer traditional liquid vaccines.

"Childhood vaccines that can be inhaled and delivered directly to mucosal surfaces have the potential to offer significant advantages over injection," Sievers said. "Not only might they reduce the risk of infection from HIV, hepatitis, and other serious diseases due to unsterilized needles, they may prove more effective against disease."

"Many serious infections, such as the measles virus, can enter the body through inhalation. Measles vaccine dry powders have the potential to effectively vaccinate infants, children and adults by inhalation, avoiding the problems associated with liquid vaccines delivered by injection," he added.

Although made for developing countries, the technology eventually could become the basis for a new generation of inhalable — and ouchless vaccines — in the United States and elsewhere. So far, an inhalable vaccine is available for only one disease. It is a wet mist vaccine for influenza.

Sievers, once an atmospheric scientist and who now is with Department of Chemistry and Biochemistry and Center for Pharmaceutical Biotechnology, University of Colorado, Boulder, took inspiration for the new vaccine from research on how people inhale tiny airborne droplets of air pollutants.

To create an inhalable vaccine, Sievers and his team of students and researchers developed a patented process known as the "Carbon Dioxide-Assisted Nebulization with a Bubble Dryer," called CAN-BD. The weakened measles virus is mixed with "supercritical" carbon dioxide — part gas, part liquid — to produce microscopic bubbles and droplets, which then are dried to make an inhalable powder.

The powder is puffed into a small, cylindrical, plastic sack, with an opening like the neck of a plastic water bottle, and administered. "By taking one deep breath from the sack, a child could be effectively vaccinated," Sievers said.

In animal tests, the inhaler has been just as effective in delivering measles vaccine as the traditional injection, the researchers say. They now are working on an inexpensive dry powder inhaler that would deliver measles or influenza vaccines to developing nations and could be used elsewhere. In replacing injections, the new method also would help reach those who refuse inoculations because of their fear of needles. The researchers say that the vaccine could be produced for about 26 cents a dose.

If the inhaler passes final safety and effectiveness tests, the Serum Institute of India Ltd. expects a demand growing to 400 million doses of measles vaccine a year, according to Sievers.

"Human clinical trials are expected to begin next year in India, after animal safety studies are completed this year," Sievers said. "About two-thirds of the world's deaths due to measles occur in that nation. Worldwide, several hundred people die every day from measles-related disease," he added.

In earlier research in the 1980s in Mexico during a measles outbreak, 3 million children received a measles vaccine by inhaling a wet mist aerosol and those who took part in the test had a lower rate of developing measles than those who received a vaccine by injection, according to Sievers. "The problem with that method," he said, "was that the wet mists required power or batteries to generate the aerosol and the liquid vaccines had to be freshly made up and kept on ice and the nebulizer that delivers the dose had to be cleaned. The new, inexpensive dry aerosol dispenser doesn't need to be cleaned and doesn't require power," he said.

The study has been conducted with a grant from the Foundation for the National Institutes of Health as part of the Grand Challenges in Global Health Initiative of the Bill and Melinda Gates Foundation.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Needle-free, Inhalant Powder Measles Vaccine Could Save Thousands Of Lives." ScienceDaily. ScienceDaily, 18 August 2009. <www.sciencedaily.com/releases/2009/08/090816170913.htm>.
American Chemical Society. (2009, August 18). Needle-free, Inhalant Powder Measles Vaccine Could Save Thousands Of Lives. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2009/08/090816170913.htm
American Chemical Society. "Needle-free, Inhalant Powder Measles Vaccine Could Save Thousands Of Lives." ScienceDaily. www.sciencedaily.com/releases/2009/08/090816170913.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins